Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Sorafenib
Synonyms
Therapy Description

Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is FDA approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Sorafenib Nexavar BAY 43-9006 CSF1R Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 RAF Inhibitor (Pan) 28 RET Inhibitor 53 VEGFR2 Inhibitor 37 Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is FDA approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 F590_D593delinsGP hematologic cancer predicted - sensitive Sorafenib Preclinical - Biochemical Actionable In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation in cells expressing FLT3 F590_D593delinsGP in culture (PMID: 37246158). 37246158
PIK3CA mutant hepatocellular carcinoma decreased response Sorafenib Clinical Study - Cohort Actionable In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072). 30373752
RET R886W Advanced Solid Tumor sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing RET R886W were sensitive to treatment with Nexavar (sorafenib) in culture, demonstrating reduced cell proliferation (PMID: 21551259). 21551259
BRAF D594G melanoma sensitive Sorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, Nexavar (sorafenib) treatment inhibited Erk phosphorylation, reduced growth, and induced mitochondrial depolarization and apoptosis in melanoma cells harboring BRAF D594G in culture, and inhibited tumor growth and induced regression in a cell line xenograft model (PMID: 18794803). 18794803
KIT W557_K558del KIT T670I Advanced Solid Tumor sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited proliferation and induced apoptosis of transformed cells expressing a KIT W557_K558del/T670I double mutation in culture (PMID: 17699867). 17699867
RET M918T colorectal cancer sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273). 17664273
FLT3 exon 14 ins FLT3 Y842C acute myeloid leukemia resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 Y842C demonstrated resistance to Nexavar (sorafenib) in culture (Blood 2009 114:3776). detail...
FLT3 S574del hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) decreased proliferation in transformed cells expressing FLT3 S574del in culture (PMID: 33914060). 33914060
RET mutant cancer sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273). 17664273
BRAF V504_R506dup Advanced Solid Tumor predicted - resistant Sorafenib Preclinical - Biochemical Actionable In a preclinical study, transformed cells overexpressing BRAF V504_R506dup were resistant to Nexavar (sorafenib) in culture (PMID: 30575814). 30575814
BRAF V504_R506dup Advanced Solid Tumor predicted - resistant Sorafenib Preclinical - Biochemical Actionable In a preclinical study, cells expressing BRAF V504_R506dup were resistant to treatment with Nexavar (sorafenib) in culture (PMID: 34108213). 34108213
CBL Y371H FLT3 wild-type hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543). 31309543
FLT3 exon 14 ins FLT3 N841K acute myeloid leukemia resistant Sorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, FLT3 N841K was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Nexavar (sorafenib) (PMID: 35344039). 35344039
BRAF L485_P490delinsFS Advanced Solid Tumor predicted - sensitive Sorafenib Preclinical - Biochemical Actionable In a preclinical study, Nexavar (sorafenib) inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). 37656784
FLT3 exon 14 ins FLT3 Y842H Advanced Solid Tumor decreased response Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356). 23392356
FLT3 over exp hepatocellular carcinoma sensitive Sorafenib Clinical Study Actionable In an observational clinical study, hepatocellular carcinoma patients harboring FLT3 overexpression treated with Nexavar (sorafenib) demonstrated improved overall survival (24.9 months (n=67)) when compared to patients with FLT3 overexpression who received a control treatment (10.0 months (n=49)) or patients with decreased FLT3 expression treated with Nexavar (sorafenib) (16.0 months (n=71)) (PMID: 32332018). 32332018
FLT3 over exp hepatocellular carcinoma sensitive Sorafenib Preclinical - Pdx Actionable In a preclinical study, Nexavar (sorafenib) inhibited tumor growth and reduced the percentage of tumor cells expressing Ki-67 in patient-derived xenograft (PDX) models of hepatocellular carcinoma harboring FLT3 overexpression, but had no effect on tumor growth inhibition or Ki-67 expression compared to control treatments in PDX models of HCC harboring decreased FLT3 expression (PMID: 32332018). 32332018
BRAF T529N BRAF V600E Advanced Solid Tumor conflicting Sorafenib Preclinical Actionable In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to Nexavar (sorafenib)-mediated inhibition of Erk phosphorylation but were equally as sensitive to Nexavar (sorafenib)-mediated growth inhibition as transformed cells expressing BRAF V600E in culture (PMID: 20538618). 20538618
BRAF L597R melanoma predicted - sensitive Sorafenib Preclinical - Patient cell culture Actionable In a preclinical study, Nexavar (sorafenib) treatment inhibited viability of patient-derived melanoma cells harboring BRAF L597R in culture (PMID: 23715574). 23715574
BRAF R506_K507insLLR Advanced Solid Tumor predicted - resistant Sorafenib Preclinical - Biochemical Actionable In a preclinical study, cells expressing BRAF R506_K507insLLR were resistant to treatment with Nexavar (sorafenib) in culture (PMID: 34108213). 34108213
KIT D816V hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of transformed hematologic cells expressing KIT D816V in culture (PMID: 31309543). 31309543
KIT D816V hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632). 17229632
FLT3 exon 14 ins FLT3 D835I acute myeloid leukemia predicted - resistant Sorafenib Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) and FLT3 D835I demonstrated resistance to Nexavar (sorafenib) treatment in culture (PMID: 27908881). 27908881
FLT3 exon 14 ins FLT3 Y842D hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells expressing FLT3-ITD with FLT3 Y842D were resistant to Nexavar (sorafenib) treatment in culture (PMID: 19318574). 19318574
KIT N505I melanoma sensitive Sorafenib Preclinical Actionable In a preclinical study, KIT N505I induced phosphorylation of KIT, ERK, and AKT, and was inhibited by Nexavar (sorafenib) in cell culture of melanocytes, demonstrating sensitivity of N505I to sorafenib (PMID: 24317392). 24317392
FLT3 exon 14 ins FLT3 F691L FLT3 D835I acute myeloid leukemia predicted - resistant Sorafenib Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) with FLT3 F691L and FLT3 D835I demonstrated resistance to Nexavar (sorafenib) treatment in culture (PMID: 27908881). 27908881
BRAF K601E melanoma predicted - sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) treatment induced limited apoptosis and inhibited growth of melanoma cells harboring BRAF K601E in culture (PMID: 18794803). 18794803
CBL Q365_E366insSK FLT3 pos hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Q365_E366insSK in culture (PMID: 31943762). 31943762
CBL Y371del FLT3 pos hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371del in culture (PMID: 31943762). 31943762
BRAF G469V lung non-small cell carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a clinical case study, a patient with synchronous BRAF wild-type hepatocellular carcinoma (HCC) and non-small cell lung cancer harboring BRAF G469V demonstrated a partial response in primary lung lesions, complete response in the lung metastasis, and stability of the HCC following treatment with Nexavar (sorafenib) (PMID: 27388325). 27388325
FLT3 exon 14 ins FLT3 A627P hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells co-expressing FLT3 ITD and FLT3 A627P were resistant to treatment with Nexavar (sorafenib) in culture (PMID: 22858906). 22858906
FLT3 exon 15 ins acute myeloid leukemia sensitive Sorafenib Guideline Actionable Nexavar (sorafenib) is included in guidelines as maintenance therapy for patients with acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org). detail...
FLT3 I836D FLT3 I836L hematologic cancer no benefit Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) did not inhibit viability of transformed cells expressing FLT3 I836D and I836L in culture (PMID: 28077790). 28077790
RET C634Y medullary thyroid carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568; NCT00390325). 20368568
BRAF act mut melanoma no benefit Sorafenib Phase II Actionable In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203). 22394203 16880785
FLT3 exon 14 ins FLT3 G846C acute myeloid leukemia resistant Sorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, FLT3 G846C was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Nexavar (sorafenib) (PMID: 35344039). 35344039
FLT3 V592G acute myeloid leukemia predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a clinical case study, Nexavar (sorafenib) and Droxia (hydroxyurea) treatment resulted in complete remission with no minimal residual disease, and continued Nexavar (sorafenib) treatment plus Vidaza (azacytidine) treatment resulted in sustained response for at least 60 months in a patient with acute myeloid leukemia harboring FLT3 V592G, along with NPM1 W288fs and TET2 T556fs (PMID: 32984009). 32984009
PTEN mutant hepatocellular carcinoma decreased response Sorafenib Clinical Study - Cohort Actionable In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072). 30373752
CBL Q365_E366insSK FLT3 wild-type hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Q365_E366insSK and wild-type FLT3 in culture (PMID: 31309543). 31309543
FLT3 exon 14 ins JAK3 V722I acute myeloid leukemia predicted - resistant Sorafenib Case Reports/Case Series Actionable In a clinical case study, a patient with acute myeloid leukemia harboring a FLT3-ITD mutation treated with Nexavar (sorafenib) was found to have acquired a JAK3 V722I mutation with a variant allele frequency of 49% upon relapse (PMID: 33149267). 33149267
RET C634R medullary thyroid carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a Phase II trial, Nexavar (sorafenib) treatment resulted in a partial response in 1 and stable disease in another patient with medullary thyroid carcinoma harboring RET C634R (PMID: 20368568; NCT00390325). 20368568
BRAF L485_T488delinsF Advanced Solid Tumor predicted - sensitive Sorafenib Preclinical - Biochemical Actionable In a preclinical study, Nexavar (sorafenib) inhibited ERK and MEK signaling in cells expressing BRAF L485_T488delinsF in culture (PMID: 37656784). 37656784
CBL Y371H FLT3 pos hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762). 31943762
FLT3 exon 14 ins FLT3 D835Y acute myeloid leukemia resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, an acute myeloid cell line harboring FLT3 internal tandem duplication (ITD) and FLT3 D835Y did not demonstrate sensitivity to Nexavar (sorafenib) treatment in culture (PMID: 31751472). 31751472
FLT3 exon 14 ins FLT3 D835Y acute myeloid leukemia resistant Sorafenib Case Reports/Case Series Actionable In a clinical case study, FLT3 D835Y was identified as an acquired resistance mutation in a patient with acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD) whose disease progressed on Nexavar (sorafenib) after initial response (PMID: 27908881). 27908881
FLT3 exon 14 ins FLT3 D835Y acute myeloid leukemia resistant Sorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, FLT3 D835Y was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Nexavar (sorafenib) (PMID: 35344039). 35344039
FLT3 exon 14 ins FLT3 D835Y acute myeloid leukemia resistant Sorafenib Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated resistance to Nexavar (sorafenib) treatment in culture (PMID: 27908881). 27908881
FLT3 I836S hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited viability in transformed cells expressing FLT3 I836S in culture (PMID: 28077790). 28077790
FLT3 D835N hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited viability in transformed cells expressing FLT3 D835N in culture (PMID: 28077790). 28077790
BRAF T529I BRAF V600E Advanced Solid Tumor predicted - sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618). 20538618
RET C634R Advanced Solid Tumor sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of cells expressing RET C634R in culture (PMID: 17664273). 17664273
RET C634R Advanced Solid Tumor sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET kinase activity and proliferation in transformed cells expressing RET C634R in culture (PMID: 16507829). 16507829
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 D835Y demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286). 34768286
TSC2 mutant hepatocellular carcinoma decreased response Sorafenib Clinical Study - Cohort Actionable In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072). 30373752
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FLT3-ITD, FLT3 F691L, and FLT3 Y842H demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286). 34768286
RET C634W medullary thyroid carcinoma sensitive Sorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and inhibited tumor growth in cell line xenograft models of medullary thyroid carcinoma harboring RET C634W (PMID: 16507829). 16507829
FLT3 exon 14 ins IDH2 R140Q acute myeloid leukemia predicted - resistant Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) failed to inhibit growth of cells isolated from a transgenic mouse model of acute myeloid leukemia harboring a FLT3-ITD mutation and IDH2 R140Q in culture (PMID: 33268594). 33268594
FLT3 exon 14 ins FLT3 V843A acute myeloid leukemia resistant Sorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, FLT3 V843A was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Nexavar (sorafenib) when administered once daily or 3 days per week (PMID: 35344039). 35344039
FLT3 E573del hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) decreased proliferation in transformed cells expressing FLT3 E573del in culture (PMID: 33914060). 33914060
KIT P577_D579del thymic carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a clinical case report, a patient with advanced thymic carcinoma harboring KIT P577_D579del demonstrated response to treatment with Nexavar (sorafenib), with a decrease in tumor size (PMID: 20970876). 20970876
KIT P551_V555del gastrointestinal stromal tumor sensitive Sorafenib Preclinical - Pdx Actionable In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555del (PMID: 19139124). 19139124
BRAF wild-type melanoma predicted - sensitive Sorafenib Preclinical - Patient cell culture Actionable In a preclinical study, Nexavar (sorafenib) treatment inhibited viability of patient-derived wild-type BRAF melanoma cells in culture (PMID: 23715574). 23715574
FLT3 N676K acute myeloid leukemia predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a clinical case study, a patient with acute myeloid leukemia harboring FLT3 N676K, along with NRAS G12A, KRAS G12D, ASXL1 G629fs, and GATA2 M388fs, responded to Nexavar (sorafenib) treatment (PMID: 32984009). 32984009
RET M918T medullary thyroid carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 10% (1/10) and stable disease in 90% (9/10) of patients with medullary thyroid carcinoma harboring RET M918T (PMID: 20368568; NCT00390325). 20368568
FLT3 Q577_Y589delinsPSD hematologic cancer predicted - sensitive Sorafenib Preclinical - Biochemical Actionable In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation in cells expressing FLT3 Q577_Y589delinsPSD in culture (PMID: 37246158). 37246158
KIT V560D Advanced Solid Tumor sensitive Sorafenib Preclinical Actionable In a preclinical study, transformed cells expressing KIT V560D were sensitive to Nexavar (sorafenib) in culture (PMID: 22665524). 22665524
FLT3 exon 14 ins FLT3 D835V hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286). 34768286
RET C634F medullary thyroid carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568; NCT00390325). 20368568
FGFR1 over exp renal cell carcinoma not applicable Sorafenib Phase II Emerging In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027). 25900027
BRAF V600E colorectal cancer sensitive Sorafenib Preclinical Actionable In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690). 24885690
BRAF N486_P490del pancreatic ductal adenocarcinoma sensitive Sorafenib Preclinical - Patient cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited growth of organoids derived from pancreatic ductal adenocarcinoma patients harboring BRAF N486_P490del in culture (PMID: 37656784). 37656784
FLT3 S941_F942insRVS hematologic cancer predicted - sensitive Sorafenib Preclinical - Biochemical Actionable In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation in cells expressing FLT3 S941_F942insRVS in culture (PMID: 37246158). 37246158
FLT3 exon 14 ins FLT3 F691L Advanced Solid Tumor resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356). 23392356
KIT V559D KIT D820Y Advanced Solid Tumor sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867). 17699867
FLT3 Y572del hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) decreased proliferation in transformed cells expressing FLT3 Y572del in culture (PMID: 33914060). 33914060
BRAF T529M BRAF V600E Advanced Solid Tumor predicted - sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618). 20538618
KIT P551_V555delinsTL gastrointestinal stromal tumor sensitive Sorafenib Preclinical - Pdx Actionable In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555delinsTL (PMID: 19139124). 19139124
BRAF V487_P492delinsA pancreatic carcinoma sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited colony formation in a pancreatic carcinoma cell line harboring BRAF V487_P492delinsA in culture (PMID: 37656784). 37656784
FLT3 G846D hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, a cell line expressing FLT3 G846D was resistant to Nexavar (sorafenib) in culture (PMID: 38049555). 38049555
FLT3 D835K FLT3 D835L hematologic cancer no benefit Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) did not inhibit viability of transformed cells expressing FLT3 D835L and D835K in culture (PMID: 28077790). 28077790
FLT3 exon 14 ins FLT3 A848P Advanced Solid Tumor decreased response Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356). 23392356
TSC1 mutant hepatocellular carcinoma decreased response Sorafenib Clinical Study - Cohort Actionable In a clinical case study, Nexavar (sorafenib) treatment of patients with hepatocellular carcinoma harboring Mtor pathway mutations in PIK3CA, PTEN, TSC2, or TSC1 (n=12), resulted in a lower disease control rate (8.3% vs. 40.2%), shorter progression-free survival (1.9 months vs. 5.3 months) and shorter overall survival (10.4 months vs. 17.9 months) compared to patients without mutations in this pathway (n=67) (PMID: 30373752; NCT01775072). 30373752
FLT3 rearrange myeloid neoplasm sensitive Sorafenib Guideline Actionable Nexavar (sorafenib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a FLT3 rearrangement (NCCN.org). detail...
FLT3 exon 14 ins hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) treatment inhibited growth of transformed cells expressing a FLT3-ITD in culture (PMID: 31511612). 31511612
FLT3 exon 14 ins hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543). 31309543
FLT3 amp colorectal cancer predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a clinical case study, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357). 25848357
FLT3 exon 14 ins FLT3 D835Y hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D835Y demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286). 34768286
BRAF G469E melanoma sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) treatment induced apoptosis and mitochondrial depolarization, and inhibited growth of melanoma cells harboring BRAF G469E in culture (PMID: 18794803). 18794803
KIT D820Y melanoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a clinical case study, Nexavar (sorafenib) treatment resulted in stable disease with 27% reduction in target lesions at 4 weeks in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153). 20372153
FLT3 exon 14 ins FLT3 Y842H hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 Y842H demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286). 34768286
KIT D820E thymic carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405). 19461405
FLT3 exon 14 ins FLT3 D839G hematologic cancer resistant Sorafenib Preclinical - Biochemical Actionable In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 D839G demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286). 34768286
BRAF N486_P490del ovarian cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited colony formation in an ovarian cancer cell line harboring BRAF N486_P490del in culture (PMID: 37656784). 37656784
FLT3 exon 14 ins FLT3 D835H acute myeloid leukemia resistant Sorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, FLT3 D835H was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Nexavar (sorafenib) (PMID: 35344039). 35344039
FLT3 exon 14 ins FLT3 A848P hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, cells expressing FLT3-ITD with FLT3 A848P were resistant to Nexavar (sorafenib) in culture (PMID: 20520641). 20520641
FLT3 D835Y hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells expressing FLT3 D835Y were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543). 31309543
FLT3 D835Y hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, a cell line expressing FLT3 D835Y was resistant to Nexavar (sorafenib) in culture (PMID: 38049555). 38049555
FLT3 D835A hematologic cancer no benefit Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) did not inhibit viability in transformed cells expressing FLT3 D835A in culture (PMID: 28077790). 28077790
FLT3 I836T hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). 28077790
FLT3 D586_D593delinsGG hematologic cancer predicted - sensitive Sorafenib Preclinical - Biochemical Actionable In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation in cells expressing FLT3 D586_D593delinsGG in culture (PMID: 37246158). 37246158
KIT D816V acute myeloid leukemia resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) did not inhibit Kit phosphorylation or growth of erythroleukemia cells expressing KIT D816V in culture (PMID: 31309543). 31309543
FLT3 Q575del hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) decreased downstream signaling and proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). 33914060
RET V804M Advanced Solid Tumor sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET V804M in culture (PMID: 16507829). 16507829
FLT3 exon 14 ins FLT3 F691L hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286). 34768286
FLT3 exon 14 ins FLT3 F691L hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543). 31309543
RET rearrange papillary thyroid carcinoma sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and activation of downstream signaling, and decreased growth of papillary thyroid carcinoma cells harboring the RET/PTC1 oncogene in culture (PMID: 17664273). 17664273
BRAF G469E nasopharynx carcinoma predicted - sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited growth of a nasopharyngeal carcinoma cell line expressing BRAF G469E in culture (Cancer Res (2024) 84 (7_Supplement): LB412). detail...
RET C618R medullary thyroid carcinoma predicted - sensitive Sorafenib Case Reports/Case Series Actionable In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C618R (PMID: 20368568; NCT00390325). 20368568
FLT3 K614_G617del hematologic cancer predicted - sensitive Sorafenib Preclinical - Biochemical Actionable In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation in cells expressing FLT3 K614_G617del in culture (PMID: 37246158). 37246158
RET M918T Advanced Solid Tumor sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased proliferation of cells expressing RET M918T in culture (PMID: 17664273). 17664273
RET S891A Advanced Solid Tumor sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation in cells expressing RET S891A in culture (PMID: 17664273). 17664273
RET C634W thyroid gland carcinoma sensitive Sorafenib Preclinical Actionable In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273). 17664273
BRAF V600E melanoma no benefit Sorafenib Phase II Actionable In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203). 22394203 16880785
FLT3 D835G hematologic cancer sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited viability in transformed cells expressing FLT3 D835G in culture (PMID: 28077790). 28077790
FLT3 exon 14 ins FLT3 F621L acute myeloid leukemia sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication (ITD) and expressing FLT3 F621L demonstrated sensitivity to Nexavar (sorafenib) in culture (Blood 2009 114:3776). detail...
FLT3 exon 14 ins FLT3 F691I Advanced Solid Tumor resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Nexavar (sorafenib) in culture (PMID: 23392356). 23392356
FLT3 exon 14 ins acute myeloid leukemia sensitive Sorafenib Guideline Actionable Nexavar (sorafenib) is included in guidelines as maintenance therapy for patients with acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org). detail...
FLT3 exon 14 ins acute myeloid leukemia sensitive Sorafenib Preclinical - Patient cell culture Actionable In a preclinical study, FLT3-ITD mutations correlated with sensitivity to Nexavar (sorafenib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627). 30333627
FLT3 exon 14 ins acute myeloid leukemia sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited Flt3 phosphorylation and growth of acute myeloid leukemia cell lines harboring FLT3 exon 14 insertions (ITD) in culture (PMID: 31309543). 31309543
BRAF L485_P490delinsY lung non-small cell carcinoma sensitive Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Nexavar (sorafenib) inhibited colony formation in a non-small cell lung cancer cell line harboring BRAF L485_P490delinsY in culture (PMID: 37656784). 37656784
FLT3 exon 14 ins FLT3 D835F acute myeloid leukemia predicted - resistant Sorafenib Case Reports/Case Series Actionable In a clinical case study, FLT3 D835F was identified as an acquired resistance mutation in a patient with acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD) whose disease progressed on Nexavar (sorafenib) after initial response (PMID: 24227820). 24227820

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03563170 Phase Ib/II Aldoxorubicin + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Sorafenib Sorafenib QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Withdrawn USA 0
NCT02406508 Phase II Melphalan Sorafenib Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Withdrawn USA 0
NCT01801163 Phase I Sorafenib A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) Withdrawn USA 0
NCT02728050 Phase Ib/II Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT03298451 Phase III Sorafenib Durvalumab + Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BRA 10
NCT02575339 Phase Ib/II Sorafenib Sapanisertib MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Terminated USA 0
NCT01624285 Phase II Sorafenib Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer Completed USA 0
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT01817751 Phase II Valproic acid Sorafenib Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma Completed USA 0
NCT03755791 Phase III Cabozantinib Sorafenib Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) Active, not recruiting USA | TUR | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 12
NCT02560012 Phase II Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib Personalized Targeted Inhibitors Treatment in Renal Cell Cancer Terminated USA 0
NCT02412475 Phase I Cytarabine Sorafenib Vorinostat Filgrastim Daunorubicin Fludarabine Decitabine Epigenetic Reprogramming in Relapse AML Terminated USA 0
NCT01187199 Phase I Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer Active, not recruiting USA 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Terminated USA 0
NCT02227914 Phase Ib/II Oprozomib Sorafenib Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Withdrawn USA 0
NCT02779283 Phase I Dasatinib Nilotinib Ponatinib Sorafenib Cytarabine + Idarubicin Sunitinib Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed USA 0
NCT01775501 Phase II Sorafenib Fluorouracil Oxaliplatin Leucovorin Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed USA 0
NCT02406521 Phase I Pazopanib Radium Ra 223 dichloride Sorafenib Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases Completed USA 0
NCT02559778 Phase I Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) Recruiting USA | CAN 0
NCT01578109 Phase I Sorafenib Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Completed USA 0
NCT02143726 Phase II Sorafenib Everolimus Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer Unknown status USA 0
NCT02627963 Phase III Sorafenib Tivozanib A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC Completed USA | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL 0
NCT02279719 Phase Ib/II Sorafenib Amcasertib + Sorafenib Napabucasin + Sorafenib A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma Completed USA 0
NCT01197170 Phase I Erlotinib Everolimus Sorafenib Anastrozole Bevacizumab Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Completed USA 0
NCT01248247 Phase I Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study Completed USA 0
NCT02288507 Phase I Sorafenib Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer Withdrawn USA 0
NCT04039607 Phase III Lenvatinib Sorafenib Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) Active, not recruiting USA | ROU | POL | NZL | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 9
NCT02551718 Phase I Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Completed USA 0
NCT04710641 Phase II CEBPA-51 + Sorafenib Sorafenib Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2) Active, not recruiting USA 1
NCT01761266 Phase III Lenvatinib Sorafenib A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma Completed USA | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT01724606 Phase I Sorafenib Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) Completed USA 0
NCT02066181 Phase III Sorafenib Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Completed USA | CAN 0
NCT01849588 FDA approved Sorafenib Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C Terminated USA 0
NCT03434379 Phase III Atezolizumab + Bevacizumab Sorafenib A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] Completed USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | AUS 7
NCT01371981 Phase III Cytarabine + Daunorubicin + Etoposide Sorafenib Cytarabine + Etoposide Cytarabine + Mitoxantrone Asparaginase + Cytarabine Bortezomib Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA | NZL | CAN | AUS 1
NCT01754987 Phase Ib/II Sorafenib A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Completed USA 0
NCT02562755 Phase III JX-594 Sorafenib Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Completed USA | NZL | ITA | ISR | GBR | FRA | DEU | CAN | AUS 7
NCT01276210 Phase I Sorafenib Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases Completed USA 0
NCT01730937 Phase III Sorafenib Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Active, not recruiting USA | CAN | AUS 2
NCT00625378 Phase III Sorafenib Sorafenib Long Term Extension Program (STEP) Completed USA | POL | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUS 6
NCT01887717 Phase III Sorafenib Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein Terminated USA | ITA | GBR | FRA | ESP | BEL 0
NCT01015833 Phase III Doxorubicin Sorafenib Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed USA | CAN 1
NCT01900002 Phase II Sorafenib Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC) Completed USA 0
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed USA 0
NCT03412773 Phase III Tislelizumab Sorafenib Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC Completed USA | POL | ITA | GBR | FRA | ESP | DEU | CZE 3
NCT02015728 Phase I Erlotinib Everolimus Dasatinib Etoposide + Temozolomide Sorafenib Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors Unknown status USA 0
NCT05822752 Phase II Lenvatinib Sorafenib ABBV-151 + Budigalimab Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) Active, not recruiting USA | ITA | FRA | ESP 3
NCT02460991 Phase I Sorafenib Doxorubicin A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma Terminated USA 0
NCT02642913 Phase Ib/II Enzalutamide Sorafenib Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients Completed USA 0
NCT02576509 Phase III Nivolumab Sorafenib A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Completed USA | SWE | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS 7
NCT01141478 Phase I Sorafenib Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria Terminated USA 0
NCT02072486 Phase I Sorafenib Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT01620216 Phase II Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients Terminated USA 0


Additional content available in CKB BOOST